This led to FDA approval in 2019 of anti-PD1 monoclonal antibodies, nivolumab and pembrolizumab, in advanced and metastatic HNSCC resistant to chemotherapy [35]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.